Company attributes
B2X
CEO
Founder
AngelList URL
Number of Employees (Ranges)
51 – 2000
Email Address
media@octant.bio0
ahoy@octant.bio0
Full Address
1464 67th St, Emeryville, CA 94608, US0
Investors
Founded Date
2017
Total Funding Amount (USD)
110,000,000
Latest Funding Round Date
April 21, 2022
Competitors
Latest Funding Type
Patents Assigned (Count)
1
Wellfound ID
Country
Other attributes
Company Operating Status
Active
Latest Funding Round Amount (USD)
80,000,000
Public/Private
Private0
Octant has developed a multiplexed technology that uses synthetic biology, genome engineering, next-generation sequencing, and computational tools to measure the activity of thousands of receptor pathways in human cells. By linking receptor activity to genetic barcodes in a pooled fashion, Octant can screen small-molecule libraries against comprehensive sets of drug targets. These large datasets enable them to develop and apply machine learning methods to engineer small molecules that interact with multiple receptors to treat complex diseases.
Products
OCTOPUS
OCTOPUS is a method for full-plasmid sequence verification.
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.